Amylyx – AMX0035
Background
Amylyx Pharmaceuticals Inc. is a company that started in 2013 with the aim of testing a combination product called AMX0035 as a potential treatment for ALS and other neurodegenerative disorders. AMX0035 is an oral drug combining two compounds called sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA).
AMX0035 was tested in a phase 2/3 clinical trial called CENTAUR, which consisted of 137 participants recruited across 25 sites in the United States through the Northeast ALS (NEALS) Consortium. The trial was randomized, double-blind and placebo-controlled, and participants were assessed over a 24-week period for both safety and potential effect of AMX0035 on disease progression.
The clinical trial had financial support from multiple key organizations in the ALS/MND field including The ALS Association, ALS Finding a Cure and the Northeast ALS Consortium (NEALS).
Results of the trial are published in The New England Journal of Medicine here
A press release delineated the key findings of the publication as follows:
- Patients retained function longer on AMX0035 versus placebo; the study achieved its primary outcome of a difference on the Revised ALS Functional Rating Scale (ALSFRS-R)
- AMX0035 is the first investigational therapy to demonstrate statistically significant benefit on this prespecified primary outcome in people with ALS since approved therapy edaravone
- AMX0035 showed numerical benefits on secondary outcomes including measures of muscle strength, breathing, and hospitalizations
- AMX0035 was generally well tolerated with similar rates of adverse events recorded in the AMX0035 and placebo groups
The publication further indicates that the effects were seen in addition to those provided by riluzole and edaravone use, though a better understanding of this additive value observation will benefit from further study. While the treatment was considered reasonably safe and tolerable, the publication also outlines that early gastrointestinal adverse events were notable and will need monitoring in future use.
An academic editorial that comments on the trial is also available here. It outlines a cautious approach to interpreting the data while balancing that these results are indeed promising. The key points of the editorial are as follows:
- Well-designed, multi-center trial with “tantalizing preliminary data”
- Trial was enriched for individuals with more rapidly progressive disease, making interpretation difficult for the wider population of people living with ALS/MND
- Secondary outcome measures were not convincingly aligned with the affect on ALSFRS-R
- Recommendation to proceed to a confirmatory phase 3 trial with wider eligibility criteria
All participants in the trial (active drug and placebo) were also provided an option to enroll in an open-label extension where they would receive AMX0035. Data from this extension study was published in October 2020 in the journal Muscle & Nerve and demonstrated that individuals initially treated with AMX0035 lived an average of 6.5 months longer than those originally on placebo. This survival study strengthens the overall data. However, it is unknown at this time how the additional survival data will impact the next steps for Amylyx or the expert consensus opinion as to whether a confirmatory clinical trial is warranted.
On March 9, 2021, Amylyx released a statement indicating an intent to file with Health Canada for regulatory approval and to explore early access options in collaboration with the Canadian ALS Research Network (CALS). On June 14, 2021, Amylyx announced that they had submitted to Health Canada. Plans for other regions have not yet been communicated but the SAC will update this document accordingly, as the information becomes available.
On April 14, 2021, Amylyx released a global regulatory update revealing an intention to submit a Marketing Authroization Application for AMX0035 to the European Medicines Agency (EMA) by the end of 2021. To fullfill a U.S. Food and Drug Administration (FDA) request for additional placebo-controlled data, Amylyx will initiate a Phase 3 clinical trial in Europe and the United States in Q3 of 2021. Amylyx also announced an intention to discuss the best path forward for AMX0035 with other regulatory bodies worldwide with further information to be provided when it is available.
On May 12, 2021, Amylyx announced a forthcoming 48-week, randomized placebo-controlled Phase 3 clinical trial called PHOENIX. It is expected to enroll 600 participants across 55 sites in the first collaborative effort between TRICALS (Europe) and NEALS (US). The primary outcome measure will be a joint assessment of ALSFRS-R score and survival, also known as the Combined Assesssment of Function and Survival (CAFS). Secondary outcome measures will include slow vital capacity measured both in clinic and remotely, as well as patient-reported outcomes and others. On November 4, 2021, Amylyx announced the first participants dosed in the PHOENIX trial.
On November 2, 2021, Amylyx announced it had submitted a New Drug Application (NDA) to the FDA for AMX0035 and on December 29 it was announced as accepted for priority review. On January 4, 2022, it was announced that Amylyx had submitted a Marketing Authorization Application to the European Medicines Agency (EMA).
Additional information
- TUDCA clinical trial
One of the compounds in AMX0035, TUDCA, is also in a phase 3 clinical trial alone with 440 participants across 9 sites in Europe supported by the TRICALS initiative. In this trial, TUDCA will be tested for 18 months with twice per day oral dosing. A small phase 2 Italian clinical trial which suggested that TUDCA may positively affect disease progression over 54 weeks was published here in 2016.
- Sodium phenylbutyrate clinical trial
Sodium phenylbutyrate was evaluated in a small clinical trial by the NEALS consortium and published here in 2009. It was considered safe and tolerable but was not designed to determine an effect on disease progression.
Both compounds have demonstrated some success at modifying disease course in preclinical animal models.
Precautions on Self treatment
Sodium phenylbutyrate is available in some countries through prescription, approved to treat urea cycle disorders. TUDCA is widely available over the counter in many forms and as part of various supplements. It is unknown whether taking these separately will have the same affect as AMX0035, or if it is the combination that enhances the effect. Furthermore, it is unknown what the purity or active compound level of any over the counter TUDCA and sodium phenylbutyrate sources will be.
Recommendation
The SAC recommends that the Alliance communicates this as a promising set of results that are peer reviewed and achieved in a well-designed clinical trial, but also that much remains to be learned about the effect of AMX0035 in ALS/MND. The trial authors emphasize that these findings will need to be confirmed in “longer and larger trials” and the SAC encourages an approach that balances critical scientific rigour with empathy for the urgent need to have safe and effective therapies for people living with ALS/MD.
The SAC encourages any member organization to reach out to the company directly to enquire whether any plans exist for their country or region. The SAC will continue to keep the Alliance apprised of any information as it becomes known regarding next steps for Amylyx.
With regard to self treatment regimens, the SAC strongly encourages individuals to speak with their ALS physician before considering. These promising results only pertain to compounded PB and TUDCA at the concentrations and purity tested in AMX0035.
International Alliance of ALS/MND Associations
January 2022
* SAC Members Dr. Kuldip Dave (September 2020) and Dr. Caroline Ingre (April 2021) have excused themselves from the preparation of this note.
The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.